



coordinated care™

Ophthalmic Agents Gene Therapy (Luxturna)

WA.PHAR.92 Ophthalmic Agents Gene Therapy (Luxturna)

Effective Date: July 1, 2018

Background: Voretigene neparvovec-rzyl (Luxturna™) is an adeno-associated virus vector-based gene therapy managed and paid by the Health Care Authority for Medicaid members.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
J3398	INJECTION VORETIGENE NEPARVOVEC-RZYL 1 B VEC G

History

Date	Action and Summary of Changes
06/24/2020	<ul style="list-style-type: none"> New Policy Created